First Header Logo Second Header Logo

Connection

Caio Max Rocha Lima to Pancreatic Neoplasms

Back to Details
This is a "connection" page, showing publications Caio Max Rocha Lima has written about Pancreatic Neoplasms.
Caio Max Rocha Lima
Connection Strength
6.540
Pancreatic Neoplasms
  1. Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol. 2014 Apr; 73(4):839-45.
    View in: PubMed
    Score: 0.414
  2. Hosein PJ, de Lima Lopes G, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol. 2013 Apr; 36(2):151-6.
    View in: PubMed
    Score: 0.389
  3. Bayraktar S, Rocha Lima CM. Emerging cell-cycle inhibitors for pancreatic cancer therapy. Expert Opin Emerg Drugs. 2012 Dec; 17(4):571-82.
    View in: PubMed
    Score: 0.379
  4. Merchan JR, Ferrell A, Macintyre J, Ciombor KK, Levi J, Ribeiro A, Sleeman D, Flores A, Lopes G, Rocha-Lima CM. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Am J Clin Oncol. 2012 Oct; 35(5):446-50.
    View in: PubMed
    Score: 0.376
  5. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012 May 29; 12:199.
    View in: PubMed
    Score: 0.367
  6. Bayraktar S, Rocha-Lima CM. Advanced or metastatic pancreatic cancer: molecular targeted therapies. Mt Sinai J Med. 2010 Nov-Dec; 77(6):606-19.
    View in: PubMed
    Score: 0.329
  7. Ramachandran K, Miller H, Gordian E, Rocha-Lima C, Singal R. Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity. Anticancer Res. 2010 Oct; 30(10):3919-25.
    View in: PubMed
    Score: 0.327
  8. Bayraktar S, Bayraktar UD, Rocha-Lima CM. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol. 2010 Feb 14; 16(6):673-82.
    View in: PubMed
    Score: 0.314
  9. Rocha-Lima CM. New directions in the management of advanced pancreatic cancer: a review. Anticancer Drugs. 2008 Jun; 19(5):435-46.
    View in: PubMed
    Score: 0.279
  10. Vulfovich M, Rocha-Lima C. Novel advances in pancreatic cancer treatment. Expert Rev Anticancer Ther. 2008 Jun; 8(6):993-1002.
    View in: PubMed
    Score: 0.279
  11. Burris H, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist. 2008 Mar; 13(3):289-98.
    View in: PubMed
    Score: 0.274
  12. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control. 2007 Jul; 14(3):295-304.
    View in: PubMed
    Score: 0.261
  13. Storch I, Jorda M, Thurer R, Raez L, Rocha-Lima C, Vernon S, Ribeiro A. Advantage of EUS Trucut biopsy combined with fine-needle aspiration without immediate on-site cytopathologic examination. Gastrointest Endosc. 2006 Oct; 64(4):505-11.
    View in: PubMed
    Score: 0.243
  14. Lopes G, Rocha Lima CM. Docetaxel in the management of advanced pancreatic cancer. Semin Oncol. 2005 Apr; 32(2 Suppl 4):S10-23.
    View in: PubMed
    Score: 0.224
  15. Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004 Sep 15; 22(18):3776-83.
    View in: PubMed
    Score: 0.215
  16. Rocha Lima CM, Centeno B. Update on pancreatic cancer. Curr Opin Oncol. 2002 Jul; 14(4):424-30.
    View in: PubMed
    Score: 0.185
  17. Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002 Mar 01; 20(5):1182-91.
    View in: PubMed
    Score: 0.181
  18. Rocha Lima CM, Sherman CA, Brescia FJ, Brunson CY, Green MR. Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 5):46-51.
    View in: PubMed
    Score: 0.169
  19. Green MR, Harper M, Safa A, Sherman CA, Mushtaq CM, Bahadori H, Brescia FJ, Rocha Lima CM. Irinotecan in the management of patients with pancreatic cancer. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):31-3.
    View in: PubMed
    Score: 0.166
  20. Narayanan G, Hosein PJ, Beulaygue IC, Froud T, Scheffer HJ, Venkat SR, Echenique AM, Hevert EC, Livingstone AS, Rocha-Lima CM, Merchan JR, Levi JU, Yrizarry JM, Lencioni R. Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. J Vasc Interv Radiol. 2017 Mar; 28(3):342-348.
    View in: PubMed
    Score: 0.126
  21. Khushman M, Dempsey N, Maldonado JC, Loaiza-Bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-Cordovi J, Parajuli R, Pollack T, Harwood AP, Macintyre J, Tzeng CW, Merchan JR, Restrepo MH, Akunyili II, Ribeiro A, Narayanan G, Portelance L, Sleeman D, Levi JU, Lima CM, Hosein PJ. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology. 2015 Nov-Dec; 15(6):667-73.
    View in: PubMed
    Score: 0.115
  22. Liu-Mares W, Mackinnon JA, Sherman R, Fleming LE, Rocha-Lima C, Hu JJ, Lee DJ. Pancreatic cancer clusters and arsenic-contaminated drinking water wells in Florida. BMC Cancer. 2013 Mar 12; 13:111.
    View in: PubMed
    Score: 0.097
  23. Wolpin BM, O'Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM, Ritch P, Chan E, Spratlin J, Macarulla T, McWhirter E, Pezet D, Lichinitser M, Roman L, Hartford A, Morrison K, Jackson L, Vincent M, Reyno L, Hidalgo M. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013 Jul; 24(7):1792-1801.
    View in: PubMed
    Score: 0.097
  24. Narayanan G, Hosein PJ, Arora G, Barbery KJ, Froud T, Livingstone AS, Franceschi D, Rocha Lima CM, Yrizarry J. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol. 2012 Dec; 23(12):1613-21.
    View in: PubMed
    Score: 0.095
  25. Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, Chiorean EG. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013 Jan; 17(1):94-100; discussion p. 100-1.
    View in: PubMed
    Score: 0.095
  26. Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J, Bray SL, Hei Y, Feigal EG, Loh E, Fuchs CS. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012 Nov; 23(11):2834-2842.
    View in: PubMed
    Score: 0.092
  27. Kubiliun N, Ribeiro A, Fan YS, Rocha-Lima CM, Sleeman D, Merchan J, Barkin J, Levi J. EUS-FNA with rescue fluorescence in situ hybridization for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results. Gastrointest Endosc. 2011 Sep; 74(3):541-7.
    View in: PubMed
    Score: 0.086
  28. Ascunce G, Ribeiro A, Reis I, Rocha-Lima C, Sleeman D, Merchan J, Levi J. EUS visualization and direct celiac ganglia neurolysis predicts better pain relief in patients with pancreatic malignancy (with video). Gastrointest Endosc. 2011 Feb; 73(2):267-74.
    View in: PubMed
    Score: 0.084
  29. Shah SM, Ribeiro A, Levi J, Jorda M, Rocha-Lima C, Sleeman D, Hamilton-Nelson K, Ganjei-Azar P, Barkin J. EUS-guided fine needle aspiration with and without trucut biopsy of pancreatic masses. JOP. 2008 Jul 10; 9(4):422-30.
    View in: PubMed
    Score: 0.070
  30. Marsh Rde W, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM, Benson AB. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2007 Feb; 30(1):26-31.
    View in: PubMed
    Score: 0.064
  31. Khanna A, Walker GR, Livingstone AS, Arheart KL, Rocha-Lima C, Koniaris LG. Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg. 2006 May; 10(5):689-97.
    View in: PubMed
    Score: 0.060
  32. Rocha Lima CM, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Green MR. Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Williston Park). 2002 May; 16(5 Suppl 5):19-24.
    View in: PubMed
    Score: 0.046
  33. Rocha Lima CM, Urbanic JJ, Lal A, Kneuper-Hall R, Brunson CY, Green MR. Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies. Semin Oncol. 2001 Jun; 28(3 Suppl 10):34-43.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.